Modality
Multispecific
MOA
IL-17i
Target
JAK2
Pathway
Cell Cycle
TTR Amyloidosis
Development Pipeline
Preclinical
~Feb 2020
→ ~May 2021
Phase 1
~Aug 2021
→ ~Nov 2022
Phase 2
Feb 2023
→ Mar 2030
Phase 2Current
NCT05015449
913 pts·TTR Amyloidosis
2023-02→2030-03·Not yet recruiting
913 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-03-123.9y awayPh3 Readout· TTR Amyloidosis
Trial Timeline
2023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2
P2/3
Not yet…
Catalysts
Ph3 Readout
2030-03-12 · 3.9y away
TTR Amyloidosis
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05015449 | Phase 2/3 | TTR Amyloidosis | Not yet recr... | 913 | ACR20 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| SNY-2289 | Sanofi | Phase 2/3 | CD38 | |
| Fixainavolisib | Takeda | Preclinical | CDK2 | |
| Elrarapivir | Vertex Pharma | NDA/BLA | PRMT5 | |
| Rimaglumide | Biogen | Phase 1/2 | BCL-2 | |
| ARG-3458 | Argenx | Preclinical | RET | |
| GMA-5010 | Genmab | Phase 3 | JAK2 | |
| Teravorutinib | Illumina | Phase 2 | JAK2 | |
| Nidaratamab | Krystal Biotech | Preclinical | RET | |
| AXS-4984 | Axsome | Preclinical | JAK2 | |
| Doxazasiran | Axsome | Phase 1 | TIM-3 |